Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

Fig. 5

Subgroup analysis of the combination therapy group according to treatment. Kaplan–Meier analysis of overall survival (A) and progression-free survival (B) in patients receiving lenvatinib plus PD-1 antibodies, lenvatinib plus TACE/HAIF, or lenvatinib plus PD-1 antibodies and TACE/HAIF

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us